title: Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors.
authors.forename: M
authors.initials: M
authors.lastname: Gajda
authors.forename: O
authors.initials: O
authors.lastname: Camara
authors.forename: S
authors.initials: S
authors.lastname: Oppel
authors.forename: T
authors.initials: T
authors.lastname: Kroll
authors.forename: C
authors.initials: C
authors.lastname: Jörke
authors.forename: S
authors.initials: S
authors.lastname: Krauspe
authors.forename: U
authors.initials: U
authors.lastname: Hammer
authors.forename: C
authors.initials: C
authors.lastname: Rabenstein
authors.forename: M
authors.initials: M
authors.lastname: Untch
authors.forename: I B
authors.initials: IB
authors.lastname: Runnebaum
authors.forename: K
authors.initials: K
authors.lastname: Pachmann
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D020360:Neoadjuvant Therapy; D009360:Neoplastic Cells, Circulating / Q000187:drug effects*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab